Lv8
8120 积分 2020-10-11 加入
Addition of Carboplatin to Sequential Taxane-Anthracycline Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Phase III Randomized Controlled Trial
12天前
已完结
A 3D morphogenetic blueprint for metastatic outgrowth in breast cancer
1个月前
已完结
Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial
2个月前
已完结
Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial
2个月前
已完结
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial
3个月前
已完结
Lessons From Taxanes Versus Eribulin for First-Line Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the EMERALD Study
4个月前
已关闭
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
4个月前
已完结
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
4个月前
已完结
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial
6个月前
已完结
[Breast cancer treatment guidelines(2022 edition)]
9个月前
已完结
皖公网安备34019202002308
